The National Institute of Oncology (NIO) in Warsaw is developing TIL therapy, which uses T lymphocytes taken from a patient’s tumour. Prof. Piotr Rutkowski told PAP that no one in the region other than NIO is doing this.
How TIL therapy works
Cell therapies are one of the newer directions in cancer treatment. The TIL method uses the patient’s own T lymphocytes, isolated from samples taken from the tumour. According to Prof. Rutkowski, head of the Clinic of Soft Tissue, Bone and Melanoma Tumours at NIO, these are cells that have “already learned to recognise” cancer cells. The lymphocytes are multiplied in the laboratory and then given back to the patient.
Rutkowski noted that in our region of Europe, TIL therapy is not currently being developed anywhere besides NIO. He also mentioned the institute’s cooperation with Warsaw University of Technology on similar solutions, as well as a dedicated laboratory and ward where modern cell therapies are to be created and administered.
GIF approval for TILANOCELL
The specific product is TILANOCELL. In October, NIO announced that the Chief Pharmaceutical Inspectorate (GIF) had approved the manufacture of this investigational medicinal product. The approval extends the earlier decision for the Laboratory of Advanced Cell Therapies (ATMP Manufacturing Facility) in the Department of Regenerative Medicine. It allows TILANOCELL to be manufactured for clinical trials in accordance with Good Manufacturing Practice (GMP) rules.
The work is led by the Department of Regenerative Medicine at NIO. The project is funded by the Medical Research Agency (ABM) from the National Recovery Plan. The team has developed and validated procedures for isolating, multiplying, storing and quality-controlling the lymphocytes.
Ovarian cancer first, more indications possible
The first area of use is ovarian cancer. The institute is registering a non-commercial clinical trial funded by ABM. It concerns TIL immunotherapy combined with first-line chemotherapy in a selected group of patients with advanced ovarian cancer. The approval is not limited to a single indication, and TIL therapy may also be developed for other cancers. Rutkowski pointed, among others, to skin cancer and melanoma.
Still an investigational therapy
TILANOCELL remains an investigational medicinal product and is not available in standard oncology treatment. The approval concerns manufacturing for research purposes, not marketing authorisation. The NIO announcement does not include clinical results on the effectiveness of the therapy in patients with ovarian cancer.
Rutkowski also mentioned therapies using genetically modified T lymphocytes, which are also to be developed at the institute.





